Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation

Abstract

Coronary artery disease and heart failure carry concurrent risk for atrial fibrillation and life-threatening ventricular arrhythmias. We review evidence indicating that at therapeutic concentrations, ranolazine has potential for dual suppression of these arrhythmias. Mechanisms and clinical implications are discussed. © 2012 Published on behalf of the European Society of Cardiology. © The Author 2012.